Agenda
-
2:00 PM-4:00 PM EST In-Person Meeting Room
Pre-Conference: Early Career Committee Workshops - Non-CME
-
-
5:00 PM-5:30 PM EST In-Person Ballroom
Welcome to Country and Opening Session
Special Guest Alex Greenwich, MP
-
5:30 PM-6:00 PM EST In-Person Ballroom
Challenges in implementing methylation in screening and diagnostics
-
6:00 PM-6:15 PM EST In-Person Ballroom
Q&A Session
Using Slido for Live Q&A
-
9:00 AM-9:10 AM EST In-Person Ballroom
Acknowledgement of Country and Introduction by the Farrah Fawcett Foundation
-
9:10 AM-9:30 AM EST In-Person Ballroom
Farrah Fawcett Foundation Keynote Address: Update on the PLATO Study
Speakers:
Dr Duncan Charles Gilbert, MRCP FRCR PhD
Consultant Clinical Oncologist and Associate Professor in Cancer and Clinical TrialsUniversity Hospitals Sussex NHS Foundation Trust, and University College London
-
9:45 AM-10:00 AM EST In-Person Ballroom
ASCRS Update: Screening and Management of Anal Dysplasia and Squamous Cell Carcinoma
-
10:00 AM-10:15 AM EST In-Person Ballroom
Update on the expanding role of chemotherapy in the treatment of anal cancer
-
10:20 AM-10:40 AM EST In-Person Ballroom
Selected Oral Abstract Presentations: Cancer Focused - Non-CME
- Personalised Risk Prediction After Curative Intent Chemoradiotherapy for Anal Squamous Cell Carcinoma - Amanda Liesegang
- Tissue-based prognostic biomarkers in anal squamous cell carcinoma treated with chemoradiotherapy: a systematic review and meta-analysis - Liam Henderson
- Early detection of recurrent disease in anal squamous cell carcinoma following treatment - Yijun Gao
-
11:25 AM-11:40 AM EST In-Person Ballroom
The role of pelvic physiotherapy in the management of anal cancer
Speakers:
Angela Therese James, FACP Specialist Pelvic Health Physiotherapist
Founder & Specialist Pelvic Health PhysiotherapistSydney Pelvic Clinic
-
12:40 PM-1:00 PM EST In-Person Ballroom
Selected Oral Abstract Presentations: Cancer Focused - Non-CME
- Prognostic significance of tumour volume and systemic inflammation in anal squamous cell carcinoma - Liam Henderson
- Sexual Toxicity after Chemoradiation for Anal Cancer Among Men who have Sex with Men: A Qualitative Analysis of Existing Sexual Health Outcome Measures - Angelica Arzola
- A WISER way to support women with anal cancer - Mary Hayes
-
-
1:00 PM-2:00 PM EST In-Person Murphy Room
Poster Viewing/Judging
-
2:30 PM-3:00 PM EST In-Person Ballroom
Biomarkers to improve efficiency and coverage of anal cancer prevention programs
-
3:45 PM-4:00 PM EST In-Person Ballroom
Successes and challenges that might influence the roll out of anal screening programs
Speakers:
Professor Karen Veronica Canfell AC, D.Phil
Professor of Public Health & NHMRC Leadership Fellow; Lead - Cancer Elimination Collaboration; Lead - Elimination Partnership In Cervical Cancer (EPICC)Cancer Elimination Collaboration (CEC), Sydney School of Public Health, University of Sydney
-
4:15 PM-4:35 PM EST In-Person Ballroom
Selected Oral Abstract Presentations: Including Epidemiology and Biomarkers - Non-CME
- Innate and Adaptive Host Immunity Shapes Intratypic Evolution of Human Papillomaviruses in Anogenital Infection - Andrea Lisco
- Comparable Diagnostic Performance of Home Self-Collected and Clinician-Collected Anal Swabs for S5 DNA Methylation Triage: A feasible Study within the Randomised PAC Self-Swab Trial - Beinda Nedjai
- Circulating HPV DNA detection in anal high-grade squamous intraepithelial lesions - Aida Marku
- Assessing the Diagnostic Value of the ASCL1/ZNF582 Methylation Testing in Risk Groups Beyond MSMLWH - Susanne Bock
-
4:35 PM-5:05 PM EST In-Person Ballroom
Selected Oral Abstract Presentations : Screening Focus - Non-CME
- Anal cancer screening in women with HIV: interim results from the SANCA study - Christina Carlander
- Mucosal CD4+ T-cell lymphopenia and distinct transcriptomic signatures in HPV16+ anal HSIL in MSM living with HIV - Rehana Hewavisenti
- Training and validation of the ASCL1/ZNF582 methylation assay on anal swabs - Valentine Ferre
- Detection of high-grade anal dysplasia by host-cell methylation markers in anal swabs - David Chromy
- Anal cancer screening eligibility among patients diagnosed with anal squamous cell carcinoma - Finlay Pilcher
-
6:30 PM-9:30 PM EST In-Person Imperial Hotel, Erskineville
Optional Social Activity - Drag and Dine
For more information click on IANS Social Activites
-
9:00 AM-9:40 AM EST In-Person Ballroom
Acknowledgment of Country & Different Perspectives on Screening Panel
- United States - Beth Stier
- United Kingdom - Richard Gilson
- Europe - David Chromy
- Philippines - Carlos San Mateo
- Australia - Mary Poynten
- China – Long Sui
- Japan - Naokatsu Ando
- Argentina – Luciana La Rosa
Panelist:
- Mary Poynten, MBBS, MPH, PHD, Associate Professor, Kirby Institute, UNSW Sydney
- David Chromy, MD PhD, Medical University of Vienna
- Dr. Carlos Manuel Angeles San Mateo, MD, MA, FACS, DABS, DipABLM, FASCRS, Colorectal Surgeon, Alkimiya Surgical Systems, PC
- Long Sui, Medical Practitioner Qualification Certificate;Medical Practitioner License, Chief Physician, Professor, Obstetrics and Gynecology Hospital,Fudan University
- Naokatsu Ando, MD, PhD, Head of HIV outpatient clinic, Japan Institute for Health Security
- Elizabeth Stier, MD, Professor, Boston University Chobanian and Avedisian School of Medicine
- Luciana La Rosa, MD
- Professor Richard Gilson, MD FRCP, Professor of Sexual Health and HIV Medicine, University College London
-
9:40 AM-9:50 AM EST In-Person Ballroom
Q&A Session
Using Slido for Live Q&A
-
9:50 AM-10:30 AM EST In-Person Ballroom
Selected Oral Abstract Presentations: Screening and Guidelines, High Risk Groups - Non-CME
- Anal Cancer Screening Performance and Anal HSIL Outcomes in HIV-negative Women with a History of Genital Precancer or Cancer: Baseline and 12-Month Results of the SWAN Study - Michael Gaisa
- High-risk human papillomavirus genotype prevalence and HPV screening test performance among people living with HIV in the ANCHOR screening cohort - Joel Palefsky
- Development of a Locally-Adapted Tool for Implementation of Anal Cancer Screening in Primary Care - Anna Yeung
- Prevalence and Risk Factors for Anal Human Papillomavirus and Dysplasia in People with HIV and Solid Organ Transplant Recipients - Mariame Sylla
- Analysis the results of anal cancer screening in women with vulvar precancerous lesions - Zeyang Chen
-
11:25 AM-11:50 AM EST In-Person Ballroom
Implementation Panel Discussion
- Needs Assessment: Maaza Abdi
- Dissemination: Elliot Arsoniadis
- Growing the Workforce: Will DeWitt
- Measurement of Success: Ann Burchell
- Lobby/Advocacy: Mary-Jo Murphy
-
11:50 AM-12:00 PM EST In-Person Ballroom
Q&A Session
Using Slido for Live Q&A
-
12:00 PM-1:00 PM EST In-Person Ballroom
Selected Oral Abstract Presentations: Screening & Guidelines High-Risk Groups - Non-CME
- Risk of anal intraepithelial neoplasia in situ and invasive anal cancer among solid organ transplant recipients in the United States - Cameron Haas
- Long-term follow-up of participants in the Study of the Prevention of Anal Cancer (SPANC) - Clare Dyer
- Balancing Detection and Resource Utilization in Anal Cancer Screening for People with HIV: A Multi-Guideline Evaluation - Joseph Terlizzi
- HPV-16 based sequential triage improves biopsy efficiency for anal HSIL in non-HIV-infected women - Qing Cong
- A systematic review of decisional needs for anal cancer screening among high-risk populations - Junqiang Zhao
- Negative Predictive Value of a Negative High-Resolution Anoscopy with Concurrent Negative hrHPV Testing: A Time-to-Event Analysis in a High-Risk Cohort - Gregory Barnell
-
-
1:00 PM-2:00 PM EST In-Person Murphy Room
Poster Viewing/Judging
-
2:00 PM-2:20 PM EST In-Person Ballroom
Standardising Clinical Trial Design - Definitions, AE collection, Cure vs. Clearance
Speakers:
Dr David Finch, MBChB, PhD, BSc
Higher Surgical Trainee (Colorectal)Manchester Royal Infirmary
-
Speakers:
Dr Duncan Charles Gilbert, MRCP FRCR PhD
Consultant Clinical Oncologist and Associate Professor in Cancer and Clinical TrialsUniversity Hospitals Sussex NHS Foundation Trust, and University College London
-
3:45 PM-4:20 PM EST In-Person Ballroom
Selected Oral Abstract Presentations: Implementation - Non-CME
- Anal Cancer HSIL Outcomes Research (ANCHOR): Characteristics of Those in the Treatment Arm that Developed Cancers Compared with Those Without Cancer - Julia Pugliese
- Anal Cancer Screening Practices and Barriers to Widespread Implementation: Insights from an International Anal Neoplasia Society Cross-Sectional Survey - Rachael Pellegrino
- Health System and Clinician Needs for Adoption of Anal Cancer Screening in Ontario, Canada: A Qualitative Interview Study - Ann Burchell
- Integrating Sexual Wellbeing into Anal Cancer Screening and HSIL Treatment for GBMSM - Matthew Marino
- The ASSETS-NY Coalition: Leveraging a Community-Driven Coalition to Improve the Anal Cancer Screening Continuum in New York City - Will DeWitt
- Social vulnerability and home-based self-sampling vs. clinician sampling for anal precancer screening: The Prevent Anal Cancer Self-Swab Study - Alan Nyitray
- Building Bridges and Breaking Language Barriers: The First Five Years of the IANS Spanish-Portuguese Task Force - Luciana La Rosa
-
4:25 PM-5:00 PM EST In-Person Ballroom
Selected Oral Abstract Presentations: Treatment (Non-CME)
- Analysis of the Efficacy and Safety of Laser Therapy for High-Grade Anal Intraepithelial Neoplasia in HIV-Negative Women - Qing Cong
- Post-Treatment Anal HSIL Recurrence in a Real-Life High-Risk Screening Population - Wilner Kan
- Lesion Extent as a Morphologic Marker of Biopsy-Confirmed Anal HSIL During High-Resolution Anoscopy: A Mexican Referral Cohort - Manuel Valencia Echeverria
- Radiofrequency Ablation produces sustained clearance of Anal High-Grade Squamous Intraepithelial Lesions - Cameron Douglas
- Anal HSIL despite treatment: Findings from the VIVA Trial - Helen Stankiewicz Karita
-
6:30 PM-11:30 PM EST In-Person Watersedge
Optional Social Activity - Watersedge Dinner
For more information click on IANS Social Activites
-
Speakers:
John Michael Berry-Lawhorn, MD
Retired Clinical Professor of Medicine and Attending PhysicianUCSF and Farabi Wellness Center
-
9:20 AM-10:35 AM EST In-Person Ballroom
Treatment of Anal Dysplasia
9:20 AM Which Treatment Should We Use? - Naomi Jay
9:35 AM Evidence-Based Follow-Up Plans - Sally Murray
9:50 AM Can You Ever Discharge? - Gary Clifford
10:05 AM Treatment Guidelines - Tamzin Cuming
10:20 AM Locally applied treatments for anal HSIL - David Chromy
Speakers:
- Sally Barbara Murray, FAChSHM, FAFPHM, MHScPHP, MPHTM, MBBS, Sexual Health Physician, Fremantle/Fiona Stanley Hospital/Royal Perth Hospital
- Gary Clifford, PhD
- Tamzin Cuming, MD, IANS President, IANS
- David Chromy, MD PhD, Medical University of Vienna
- Dr. Naomi Jay, PhD RN NP FAAN, Nurse Practitioner, Asst clinical professor of medicine (volunteer), University of California San Francisco
-
10:35 AM-10:45 AM EST In-Person Ballroom
Q&A Session
Using Slido for Live Q&A
-
Speakers:
Dr Jennifer Margaret Roberts, MBBS FRCPA
Pathologist, Senior Research FellowKirby Institute
-
11:40 AM-11:55 AM EST In-Person Ballroom
The role of HPV DNA in Determining Follow-Up of Anal Dysplasia
Speakers:
Dr Benjamin Hugh Armstrong, BBiomedSc MBBS MPH FRCPA MAIMS MASM
Director of MicrobiologyDouglass Hanly Moir Pathology
-
11:55 AM-12:30 PM EST In-Person Ballroom
Selected Oral Abstract Presentations: Treatments, Screening Diagnostics, and AI - Non-CME
- Adverse events associated with treatment for anal high-grade squamous intraepithelial lesions: A systematic review - Clare Dyer
- Addressing limitations in anal cancer screening: AI-assisted detection of precancerous lesions using high-resolution anoscopy - Reshi Suthakaran
- High-Performance Multi-Class Detection of Anal Lesions on High-Resolution Anoscopy Using Deep Learning - Jiajun Sun
- Artificial Intelligence for High-Resolution Anoscopy: First Multicontinental Validation study for Simultaneous Detection and Differentiation of Anal cancer precursors Across Different Imaging Platforms - Luis Barroso
-
-
12:30 PM-1:30 PM EST In-Person Murphy Room
Poster Viewing
-
1:30 PM-2:30 PM EST In-Person Ballroom
Panel - Learning from patient experience - using patients' perspectives to shape expectations and guide future research - Non-CME
-
3:00 PM-3:20 PM EST In-Person Ballroom
The Evolving Landscape of HPV Disease: Mechanisms, Immune Evasion, and Therapeutic Vaccines
-
Speakers:
- Dr Troy Grennan, MD MSc FRCPC, Physician Lead, HIV/STI Program, BC Centre for Disease Control
- Tamzin Cuming, MD, IANS President, IANS
